

Financial news for SNTA dated on 2016-05-03: Synta Pharmaceuticals Releases Corporate Presentation

Financial news for SNTA dated on 2016-04-28: Madrigal Pharmaceuticals Reports 21% Stake in Synta Pharmaceuticals in 13D

Financial news for SNTA dated on 2016-04-14: Mid-Afternoon Market Update: 3D Systems Shares Climb On Bank Of America Upgrade; Energy XXI Shares Tumble

Financial news for SNTA dated on 2016-04-14: Mid-Day Market Update: Seagate Drops Following Q3 Guidance; Sunedison Shares Surge

Financial news for SNTA dated on 2016-04-14: Top Performing Industries For April 14, 2016

Financial news for SNTA dated on 2016-04-14: Synta, Madrigal Report Merger Agreement; Synta Will Acquire All Outstanding Shares Of Madrigal For \$253.9M Newly Issued Shares Of Synta Stock

Financial news for SNTA dated on 2015-10-21: Morning Market Losers

Financial news for SNTA dated on 2015-10-21: Roth Capital Downgrades Synta Pharmaceuticals to Neutral, Lowers PT to \$1.00

Financial news for SNTA dated on 2015-10-20: Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

Financial news for SNTA dated on 2015-09-09: Synta Names Dr. Alan Rigby Chief Scientific Officer

Financial news for SNTA dated on 2015-08-11: Synta Pharmaceuticals Spikes to High on Report of Patents for non-Hodgkin's Lymphoma

Financial news for SNTA dated on 2015-08-06: S-3 from Synta Pharma Shows Registration for \$300M Mixed Securities Shelf Offering

Financial news for SNTA dated on 2015-08-06: Synta Reports Q2 EPS \$(0.15) vs. Est. \$(0.18)

Financial news for SNTA dated on 2015-06-02: Synta Offers Ganetesob Program Updates: First Patient Enrolled In First Phase Trial

Financial news for SNTA dated on 2015-05-07: Synta Reports Q1 Loss \$0.19 Vs Est Loss \$0.20

Financial news for SNTA dated on 2015-05-07: Synta Pharma -\$0.19 vs -\$0.20 est

Financial news for SNTA dated on 2015-04-21: FBR Capital Initiates Coverage on Synta Pharmaceuticals at Outperform, Announces \$6.00 PT

Financial news for SNTA dated on 2015-04-15: Netflix, Panera Bread Lead Wednesday's After-Hours Movers

Financial news for SNTA dated on 2015-04-13: Ignore Headline About Cowen Initiation On Synta Pharma, Was Made On April 10th

Financial news for SNTA dated on 2015-04-10: Caxton Corp. Reduces Stake In Synta Pharma From 27.57% To 21.2%

Financial news for SNTA dated on 2015-04-10: Benzinga's Top Initiations

Financial news for SNTA dated on 2015-04-10: Cowen Initiates Synta Pharmaceuticals At Outperform

Financial news for SNTA dated on 2015-04-01: QuickLogic, Sonic Corp, BioMarin Pharmaceutical Lead Wednesday's After-Hours Movers

Financial news for SNTA dated on 2015-03-31: Stocks Hitting 52-Week Lows

Financial news for SNTA dated on 2015-03-31: Morning Market Losers

Financial news for SNTA dated on 2015-03-31: Synta Pharma Prices Offering Of 22M Shares At \$1.75/Share

Financial news for SNTA dated on 2015-03-31: Benzinga's Top #PreMarket Losers

Financial news for SNTA dated on 2015-03-31: 7 Stocks You Should Be Watching Today

Financial news for SNTA dated on 2015-03-30: Books-A-Million, HomeAway, Vaalco Energy

Lead Monday's After-Hours Movers

Financial news for SNTA dated on 2015-03-30: Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for SNTA dated on 2015-03-12: Synta Reports Q4 EPS \$(0.19) vs. Est. \$(0.21)

Financial news for SNTA dated on 2015-03-12: Earnings Scheduled For March 12, 2015

Financial news for SNTA dated on 2015-02-05: Synta Outlines New Corporate Strategy

Financial news for SNTA dated on 2014-12-12: Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer

Financial news for SNTA dated on 2014-12-04: Synta Pharmaceuticals Appoints Chen Schor To EVP, COO; Marc Schneebaum SVP, CFO

Financial news for SNTA dated on 2014-11-06: Synta Pharmaceuticals Corp. Reports Q3 EPS of \$(0.19) Which May Not Compare \$(0.24) Est

Financial news for SNTA dated on 2014-11-05: Synta Announces FDA's Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib

Financial news for SNTA dated on 2014-10-29: Synta Announces Initiation Of I-SPY 2 TRIAL Of Ganetespib In Breast Cancer

Financial news for SNTA dated on 2014-08-25: InterMune's Roche Deal Sends Peer Group Up

Financial news for SNTA dated on 2014-08-06: Synta Announces Anne Whitaker CEO and President

Financial news for SNTA dated on 2014-07-21: Synta Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS

Financial news for SNTA dated on 2014-07-18: Filing from Synta Pharma Shows Prospectus Supplement for \$50M Shares

Financial news for SNTA dated on 2014-06-24: Synta Pharmaceuticals Shares Moving; May be Attributed to Roberto Pedone Street.com Article

Financial news for SNTA dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for SNTA dated on 2014-06-18: 5-Star Biotech Stock Watch: Synta Pharmaceuticals

Financial news for SNTA dated on 2014-05-08: Synta Pharmaceuticals Corp. Reports Q1 EPS of \$(0.28) vs \$(0.29) Est

Financial news for SNTA dated on 2014-03-20: Morning Market Movers

Financial news for SNTA dated on 2014-03-20: Benzinga's Top #PreMarket Gainers

Financial news for SNTA dated on 2014-03-20: Synta Shares Rise 26% Premarket on Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer

Financial news for SNTA dated on 2014-03-12: Top Trending Tickers On StockTwits For March 12

Financial news for SNTA dated on 2014-03-12: Morning Movers for March 12th, 2014

Financial news for SNTA dated on 2014-03-12: Morning Market Losers

Financial news for SNTA dated on 2014-03-12: BMO Capital Downgrades Synta Pharmaceuticals Corp. to Underperform, Lowers PT to \$1.00

Financial news for SNTA dated on 2014-03-12: Benzinga's Top #PreMarket Losers

Financial news for SNTA dated on 2014-03-12: UPDATE: Stifel Downgrades Synta Pharmaceuticals as GALAXY-2 Adjustments Further Diminish Likelihood For Success

Financial news for SNTA dated on 2014-03-12: Stifel Nicolaus Downgrades Synta Pharmaceuticals Corp. to Sell

Financial news for SNTA dated on 2014-03-11: Synta Pharmaceuticals Corp. Reports Q4 EPS of \$(0.31) vs \$(0.30) Est

Financial news for SNTA dated on 2014-03-11: Earnings Scheduled For March 11, 2014

Financial news for SNTA dated on 2014-03-03: Synta Announces Executive Management Changes, Appoints Dr. Paul A. Friedman Director

Financial news for SNTA dated on 2014-01-09: Synta Initiates Three Multicenter, Randomized Phase II/III Trials of Ganetespib In AML And High Risk MDS

Financial news for SNTA dated on 2013-11-18: Synta Pharmaceuticals Rises 6% Pre-Market, May be Attributed to Seeking Alpha Article

Financial news for SNTA dated on 2013-11-13: Stocks Hitting 52-Week Lows

Financial news for SNTA dated on 2013-11-13: Synta Prices 14M Shares at \$3.75/Share

Financial news for SNTA dated on 2013-11-12: Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for SNTA dated on 2013-10-26: Synta Presents Positive One-Year Follow-up Results for GALAXY-1 Trial of Ganetespib in NSCLC at 15th World Conference on Lung Cancer

Financial news for SNTA dated on 2013-09-28: Synta Announces Encouraging Results of Ganetespib GALAXY-1 Trial at ECC 2013

Financial news for SNTA dated on 2013-09-25: Shares of Synta Pharma Down ~1.6% But Off Session Lows Under \$6; Analyst Sees Downside on Infinity News

Financial news for SNTA dated on 2013-09-12: Shares of Synta Moving Higher Following News of Fast Track Designation for Ganetespib

Financial news for SNTA dated on 2013-08-22: These Three Speculative Small Caps Are Loved By Insiders and Institutions

Financial news for SNTA dated on 2013-08-01: Synta Pharmaceuticals Corp. Reports Q2 EPS of \$(0.33) vs \$(0.30) Est; Revenue of \$0.00 vs \$330.0K Est

Financial news for SNTA dated on 2013-08-01: Synta Provides Clinical Updates

Financial news for SNTA dated on 2013-07-29: Market Wrap for Monday, July 29: Stocks Record Moderate Losses to Start Trading Week

Financial news for SNTA dated on 2013-07-29: Adam F Tweets 'Synta Suffers from Premature Stock Promotion Syndrome'

Financial news for SNTA dated on 2013-07-29: Synta Pharmaceuticals Surges 45% on Positive ENCHANT-1 Breast Cancer Results

Financial news for SNTA dated on 2013-07-29: Synta Announces ENCHANT-1 Breast Cancer Results Support Transition to Second Stage of Trial

Financial news for SNTA dated on 2013-07-17: Synta Announces Publication of Clinical and Non-Clinical Results Demonstrating Unique Anti-angiogenic Effects of Ganetespib

Financial news for SNTA dated on 2013-07-16: JMP Securities Upgrades Synta Pharmaceuticals Corp. to Market Outperform, Announces \$11.00 PT

Financial news for SNTA dated on 2013-07-12: Synta Pharmaceuticals Spikes Lower

Financial news for SNTA dated on 2013-07-09: Synta Pharma Shares Continue Higher, Now Up 6+%; Traders Discussing Recent Insider Buys, Bruce Kovner Has Purchased ~900K Shares Since End of June

Financial news for SNTA dated on 2013-06-21: Afternoon Market Gainers

Financial news for SNTA dated on 2013-06-06: Afternoon Market Losers

Financial news for SNTA dated on 2013-06-04: Roth Says Buy the Dip in Synta Pharma as Co. Reached Ideal Patient Population in Latest Trial

Financial news for SNTA dated on 2013-06-03: Afternoon Market Losers

Financial news for SNTA dated on 2013-06-03: Morning Market Losers

Financial news for SNTA dated on 2013-06-03: Results in Synta Pharma Lung Cancer Treatment Study Shows Raised Survival Rate

Financial news for SNTA dated on 2013-05-14: Synta Pharmaceuticals Spikes Higher

Financial news for SNTA dated on 2013-05-08: BMO Capital Downgrades Synta Pharmaceuticals Corp. to Market Perform, Lowers PT to \$9.00

Financial news for SNTA dated on 2013-05-07: BMO Capital Downgrades Synta Pharmaceuticals Corp. to Market Perform

Financial news for SNTA dated on 2013-04-30: Synta Pharmaceuticals Corp. Reports Q1 EPS of \$(0.30) vs \$(0.27) Est

Financial news for SNTA dated on 2013-03-14: Mid-Afternoon Market Update: Markets Rise Higher, Synta Pharmaceuticals Falls

Financial news for SNTA dated on 2013-03-14: Synta Pharmaceuticals Corp. Reports Q4 EPS of \$(0.29) vs \$(0.26) Est

Financial news for SNTA dated on 2013-03-14: Synta Pharma Files \$300M Mixed Securities Shelf

Financial news for SNTA dated on 2013-03-14: Earnings Scheduled For March 14, 2013

Financial news for SNTA dated on 2012-12-13: Synta Pharma Prices 7M Shares at \$8.60/Share

Financial news for SNTA dated on 2012-12-12: Synta Pharmaceuticals Announces Proposed Registered Direct Offering of Common Stock

Financial news for SNTA dated on 2012-11-06: Synta Pharmaceuticals Reports Q3 EPS \$-0.25 vs \$-0.24 Est

Financial news for SNTA dated on 2012-10-24: McNicoll Lewis Vlak Maintains Synta Pharmaceuticals at Buy, Raises PT from \$10 to \$12.50

Financial news for SNTA dated on 2012-10-01: UPDATE: Jefferies Raises PT to \$22 on Synta Pharmaceuticals on GALAXY Update

Financial news for SNTA dated on 2012-10-01: Synta Pharmaceuticals Provides Updated Results from Phase 2b/3 GALAXY Trial

Financial news for SNTA dated on 2012-10-01: Jefferies & Company Maintains Synta Pharmaceuticals at Buy, Raises PT from \$15 to \$22

Financial news for SNTA dated on 2012-08-30: UPDATE: Stifel Nicolaus Initiates Synta Pharmaceuticals at Hold; Enthusiasm Outpaces Expectations

Financial news for SNTA dated on 2012-08-30: Stifel Nicolaus Initiates Coverage on Synta Pharmaceuticals at Hold

Financial news for SNTA dated on 2012-08-02: Synta Provides Clinical Update and Reports Second Quarter 2012 Financial Results

Financial news for SNTA dated on 2012-07-26: Synta Announces \$25.8 Million Registered Direct Offering of Common Stock

Financial news for SNTA dated on 2012-06-27: Synta Pharmaceuticals Spikes Lower After-Hours Despite Positive Data

Financial news for SNTA dated on 2012-06-27: UPDATE: Synta Says Ganetespib Test Results Support Moving to Phase 3 Stage

Financial news for SNTA dated on 2012-06-27: Synta Announces Results from Interim Analysis of the Randomized Phase 2b/3 GALAXY Trial Evaluating Ganetespib plus Docetaxel in Second-Line Non-Small Cell Lung Cancer

Financial news for SNTA dated on 2012-06-25: UPDATE: Jefferies Raises PT on Synta from \$7 to \$14

Financial news for SNTA dated on 2012-06-25: Stocks Hitting 52-Week Highs

Financial news for SNTA dated on 2012-06-25: UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT for Synta Pharmaceuticals

Financial news for SNTA dated on 2012-06-25: Jefferies & Company Maintains Synta Pharmaceuticals at Buy, Raises PT from \$7 to \$14

Financial news for SNTA dated on 2012-06-05: Synta Pharmaceuticals Spiking Higher on Heavy Volume; Currently at \$5.61

Financial news for SNTA dated on 2012-06-04: UPDATE: BMO Capital Markets Upgrades Synta Pharmaceuticals to Outperform on HSP90 Opportunity

Financial news for SNTA dated on 2012-06-04: BMO Capital Markets Upgrades Synta Pharmaceuticals from Market Perform to Outperform, PT Raised from \$5 to \$10

Financial news for SNTA dated on 2012-06-01: Benzinga's Top Pre-Market Losers

Financial news for SNTA dated on 2012-05-31: Today's Top Small-Cap Winners!

Financial news for SNTA dated on 2012-05-22: UPDATE: Jefferies Initiates Coverage on Synta Pharmaceuticals

Financial news for SNTA dated on 2012-05-22: Jefferies & Company Initiates Coverage on Synta Pharmaceuticals at Buy, Announces PT of \$7

Financial news for SNTA dated on 2012-02-29: Synta Announces Review of Ganetespib Results in Lung Cancer Presented at IASLC 12th Annual Targeted Therapies for the Treatment

Financial news for SNTA dated on 2012-02-22: Rodman & Renshaw Maintains Synta Market Perform, \$8 PT

Financial news for SNTA dated on 2012-02-22: Earnings Scheduled For February 22

Financial news for SNTA dated on 2012-02-06: Synta Pharmaceuticals Sells Additional 1.05M Shares of Common Stock

Financial news for SNTA dated on 2012-02-06: Notable Put Options Activity in Synta Pharmaceuticals

Financial news for SNTA dated on 2012-01-06: UPDATE: Synta Prices 7M Shares at \$4.40 Each

Financial news for SNTA dated on 2012-01-06: Synta Prices 7M Shares at \$4.40 Each

Financial news for SNTA dated on 2012-01-05: Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock; No Size Given

Financial news for SNTA dated on 2012-01-05: Rodman & Renshaw Initiates Synta Pharmaceuticals at Market Outperform

Financial news for SNTA dated on 2011-12-12: Ganetespib Potently Inhibits Multiple Signaling Pathways Active in Breast Cancer

Financial news for SNTA dated on 2011-12-09: McNicoll Lewis & Vlak Reiterates Buy, \$10 Target on Synta Pharmaceuticals

Financial news for SNTA dated on 2011-12-08: Ganetespib Shows Clinical Activity in HER2+ and Triple Negative Metastatic Breast Cancer

Financial news for SNTA dated on 2011-11-21: McNicoll Lewis & Vlak Maintains Buy Rating and \$10 PT on Synta Pharmaceuticals

Financial news for SNTA dated on 2011-11-07: Hearing ThinkEquity Initiates Synta Pharmaceuticals with a Buy and \$6 PT

Financial news for SNTA dated on 2011-09-26: MLV Maintains Buy on Synta; Price Target \$10

Financial news for SNTA dated on 2011-09-08: Synta to be Showcased in Congress as One of 13 Innovative Companies Seeking More Competitive American Business Environment

Financial news for SNTA dated on 2011-07-20: Synta Announces First Patient Treated in the GALAXY Trial(tm) a Phase 2b/3 Trial for Ganetespib in Advanced 2nd-line Non-small Cell Lung Cancer

Financial news for SNTA dated on 2011-07-07: Synta Announces Presentation of Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results

Financial news for SNTA dated on 2011-07-06: Synta Announces Presentation of Small Cell Lung Cancer Results; Synta's Ganetespib More Potent Than 17-AAG

Financial news for SNTA dated on 2011-06-13: Puts Purchased on Synta Pharmaceuticals

Financial news for SNTA dated on 2011-05-26: Synta Announces Publication of Results Showing Ganetespib Exhibits Potent Activity in Models of Cancer with Activated JAK/STAT Signaling

Financial news for SNTA dated on 2011-04-28: List of Seven Cheap Biotech Stocks Expected to Grow, Seeking Alpha Reports (CHTP, TLON, HGSI, VNDA, OREX, SNTA, VICL)

Financial news for SNTA dated on 2011-04-15: Options Brief: Synta Pharmaceuticals Corp. (SNTA)

Financial news for SNTA dated on 2011-04-15: Synta Pharmaceuticals Releases Offer Of 7.2M Shares At \$4.89 (SNTA)

Financial news for SNTA dated on 2011-04-04: Synta Announces Results Presented at AACR Further Elucidate Mechanism by Which Elesclomol Targets Cancer Cell Metabolism

Financial news for SNTA dated on 2011-04-04: Synta Announces Ganetespib Results; Inhibition of Multiple Oncogenes and Resistance Mechanisms Leads to Potent Activity in NSCLC and Strong Enhancement of Radiation Therapy

Financial news for SNTA dated on 2011-03-18: Edison Investment Comments On Synta Pharmaceuticals (SNTA)

Financial news for SNTA dated on 2011-03-11: Synta Reports Q4 EPS of \$(0.21) vs. \$(0.18)

Financial news for SNTA dated on 2011-03-11: Earnings Scheduled For March 11 (AWR, HIBB, BIOS, ANN, ARNA, LMIA, HALO, UTSI, PKT, NGPC, SNTA)

Financial news for SNTA dated on 2011-02-08: Synta Announces First Patient Treated in Phase 1 Trial of Elesclomol in Acute Myeloid Leukemia

Financial news for SNTA dated on 2011-01-12: Multiple Myeloma Research Foundation and Synta Pharmaceuticals Enter into Joint Collaboration

Financial news for SNTA dated on 2010-12-29: Magic Formula Investing Year in Review

Financial news for SNTA dated on 2010-11-11: Synta Pharmaceuticals Reports Sale of \$5M in Common Stock to Member of Board of Directors

Financial news for SNTA dated on 2010-11-04: Synta Pharmaceuticals Reports Third-Quarter 2010 Financial Results and Clinical Update

Financial news for SNTA dated on 2010-11-01: Synta Announces Gynecologic Oncology Group to Initiate Phase 2 Clinical Trial of Elesclomol

Financial news for SNTA dated on 2010-06-16: Calls Purchased on Synta Pharma (SNTA)

Financial news for SNTA dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for SNTA dated on 2010-02-19: SNTA Initiated With Sector Perform At RBC Capital

Financial news for SNTA dated on 2010-02-17: SNTA Downgraded To Hold